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ABSTRACT
Aims and Objectives: The present study is to formulate the nanosuspension containing a hydrophilic drug pramipexole dihydrochloride and 
hesperidin and to increase the drug entrapment efficiency.
Methods: Hesperidin and pramipexole dihydrochloride loaded in chitosan nanosuspension is prepared by ionic gelation method using chitosan and 
tripolyphosphate. There was no incompatibility observed between the drug and polymer through Fourier transform infrared and differential scanning 
calorimetric. Various other parameters such as particle size, zeta potential, scanning electron microscope, drug content, drug entrapment efficiency, 
and in vitro release have been utilized for the characterization of nanoparticles.
Results and Discussion: The average size of particle is 188 nm; zeta potential is 46.7 mV; drug content of 0.364±0.25 mg/ml; entrapment efficiency of 
72.8% is obtained with HPN3 formulation. The PHC1 shows the highest drug release followed by PHC2 due to low concentration of polymer and PHC4 
and PHC5 show less drug release due to high concentration of polymer. The in vitro release of PHC3 is 85.2%, initial the burst release is shown which 
is approximately 60% in 8 h; then, slow release later on drastic reduction in release rate is shown in 24 h. The in vivo study histopathological report 
confers the effective protective against rotenone induces Parkinson’s.
Conclusion: PHC3 was chosen as the best formulation due to its reduced particle size and controlled release at optimum polymer concentration 
which may be used to treat Parkinson’s disease effectively.
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INTRODUCTION
Nanoparticles are the front position of the fast-developing field 
with a potential interest in clinical medicine, delivery of drug and in 
research, as well as in different field of sciences [1]. It overcomes this 
problem due to its smaller particle size and may produce therapeutic 
effect in a particular site which offers the possibility to develop 
new therapeutics [2]. These may overcome many problems due to 
particle size, therapeutic effect in mainly due to the particular site 
which offers the possibility to develop new therapeutics [3]. Any 
drug delivery systems for brain disease have a lower efficacy due to 
insufficient bioavailability in the targeted site [4]. To overcome these 
problems, nanoparticles may be effective for its smaller particle size 
and may produce therapeutic effect in a particular site which offers the 
possibility to develop new therapeutics [3].
Is not sufficient only developing a new drug alone, to provide the 
progress in drug therapy and several research data give a disappointing 
results due to poor absorption, rapid metabolism and elimination lead 
to insufficient drug concentration at the targeted site, high fluctuation 
of the plasma levels due to unpredictable bioavailability after oral drug 
administration with poor drug solubility [5-7].
Oxidation is the main process in augmenting the energy production. 
However, oxidative stress is the predictable main cause which enhances 
the progression of disease. This condition arises when there is a 
reduction in antioxidant defenses or overproduction in reactive oxygen 
species (ROS). ROS is generated at the time of injury or inflammation. 
There are several other sites for ROS production such as mitochondrial 
electron transport. The Parkinson’s disease is more prevalent in 
person with about 65 years of age concomitant with genetic influence, 
toxins, oxidative stress, mitochondrial abnormalities, free radicals, and 
alpha-synuclein aggregation in a higher rate, which is considered to 
be the main cause for Parkinson disease. A free radical is an atom or 
group with at least one unpaired electron. It is usually an antioxidant 
molecule that has lost and needs to stabilize itself by stealing an 
electron from a nearby molecule. Antioxidant can neutralize the free 
radical by accepting or donating an electron to eliminate the unpaired 
condition [8-12]. Antioxidant is effective in the treatment of cancer, 
coronary heart disease, and neurodegenerative diseases. It is also used 
in the treatment of fried Reich ataxia [13]. Bioactive derivatives acting 
as flavonoids, stilbenoids, and alkaloids possess potent antioxidative 
and anti-inflammatory properties are now being inducing in the 
treatment of Parkinson’s disease [14]. Flavonoids like hesperidin have 
been proved to have an antioxidant effect against neurodegenerative 
disease [15].
Pramipexole is a well-known anti-parkinsonism drug which produces 
toxicity as a side effect with frequent administration in dose regimen only 
a minimal amount of the drug crosses the blood–brain barrier [16,17]. 
Pramipexole dihydrochloride is having manageable bioavailability due 
to its high first-pass metabolism and poor penetrability through blood–
brain barrier due to its hydrophilic nature. Therefore, more amount 
of the drug is required to achieve the required therapeutic activity. 
However, in nanosuspension with small amount of drug which can 
achieve the better therapeutic activity. Nanosuspension is a novel drug 
delivery system which makes the drug lipophilic and also degradation 
of drug is protected [3,6]. Due to this, the drug can able to penetrate the 
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blood–brain barrier easily for targeting the brain disorder with increased 
bioavailability [7,18] capillary endothelial cells. A2A adenosine receptor 
is a member of G protein-coupled receptor. Considering the properties 
of biodegradable nanoparticles essentially grand bioavailability, control 
release, less toxicity, and better encapsulation, they are frequently used 
as a vehicle in drug delivery. Apparently used biodegradable nanoparticle 
includes PLGA, PLA, chitosan, gelatin, polycaprolactone, and poly-alkyl-
cyanoacrylates [19,20]. Chitosan is an amino polysaccharide which 
possesses the idiosyncratic features just as non-toxicity, hydrophilicity, 
biodegradability, and mechanical strength; biocompatibility and 
physical inertness are quotidianly used as a carrier for targeted drug 
delivery in neurodegenerative disorder. It possesses higher penetration 
capacity, absorption across the mucosal epithelia, and the potential of 
binding with various ligand molecules and helps in the formation of 
stable noncomplex [21,22]. It is cationic in nature which involves in the 
formation of stable ionic complexes with multivalent anionic ions or 
polymers in various forms such as gels and micro/nanoparticles [23,24]. 
It has an antioxidant activity which is used here as a polymer produced 
from the exoskeleton of crustaceans (e.g., crabs and shrimps).
The nanosuspension is a newer drug delivery system in the 
pharmaceutical field to overcome all these above problems. The 
present study is to prepare a polymeric nanosuspension containing 
a combination of pramipexole dihydrochloride and antioxidant 
hesperidin for treating Parkinson’s disease.
METHODS
Hesperidin, pramipexole dihydrochloride, chitosan, and tripolyphosphate 
(TPP) are procured in Sigma-Aldrich. The chemicals which are used in 
the present work are of analytical grade.
Compatibility studies
Differential scanning calorimetric (DSC) analysis
DSC measurements are done by utilizing the instrument NETZSCH 
DSC 204. The samples are estimated at 0°C–300°C temperature where 
the heating rate is 5°C/min in the presence of nitrogen atmosphere. The 
aluminum pans are used for keeping the samples.
Fourier transform infrared (FTIR) analysis
FTIR analysis of pure hesperidin, chitosan, and mixture (pramipexole 
dihydrochloride, hesperidin, chitosan, and TPP) was performed and 
spectrum was obtained using FT-IR (Perkin Elmer 200 series). All 
spectra were recorded within a range of 2000–650 cm−1.
Preparation of nanoparticles containing pramipexole 
dihydrochloride
Ionotropic gelation process is adopted for the preparation of 
nanoformulation.
1. Chitosan solution was prepared by dissolving in 100 ml of 1% v/v 
acetic acid and the resulting solution is stirred at 1500 rpm in 
magnetic stirrer for 30 min (different concentrations of chitosan 
solution such as 1%, 2%, 3%, 4%, and 5% were prepared).
2. TPP solution (1%w/v) is prepared in deionized water where 100 mg 
of TPP is dissolved in 100 ml.
3. Add 100 mg pramipexole dihydrochloride and hesperidin to the 1% 
TPP solution and mix to form a homogenous mixture by stirring with 
a glass rod.
4. Add the above mixture of TPP to pramipexole dihydrochloride and 
hesperidin solution drop by drop (10 ml) to the chitosan solution 
and kept stirring at 2500 rpm for 3 h on mechanical stirrer.
Fig. 1: Differential scanning calorimetric of chitosan
Table 1: Formula for preparation
S. No Ingredients PHC1 PHC2 PHC3 PHC4 PHC5
1 Pramipexole dihydrochloride (mg) 100 100 100 100 100
2 Hesperidin (mg) 100 100 100 100 100
3 Chitosan (%) 1 2 3 4 5
4 Tripolyphosphate (ml) 100 100 100 100 100
5 1% acetic acid solution (ml) 1 1 1 1 1
135
Asian J Pharm Clin Res, Vol 11, Special Issue 4, 2018, 133-140
 Somasundaram and Kavi 
5. TPP solution is added to the aqueous solution containing pramipexole 
dihydrochloride and hesperidin with chitosan polymer, where the 
nanosuspension is formed.
6. The obtained nanosuspensions are centrifuged in high-speed 
centrifuge (Sigma) at 15,000 rpm for 10 min. Discard the sediment 
and preserve the supernatant.
7. The negative and positively charged groups in TPP as well as in 
chitosan interact themselves to form nanoparticle (Table 1).
Characterization of nanoparticles
The nanoformulation with pramipexole dihydrochloride and hesperidin 
was studied for different parameters.
Particle size
The size of particles in the nanoformulation is studied using photon 
correlation spectroscopy. The samples are diluted using ultra-purified 
water; then, it is seen in scattering at 90° angle at 25°C. The mean of 
hydrodynamic diameter for every sample is generated in triplicate.
Zeta potential
Zeta potential was characterized by utilizing an instrument as Zetasizer. 
The Zeta measurements were performed using an aqueous dip cell 
in an automatic mode by placing diluted samples in the capillary 
measurement cell and cell position is adjusted.
Surface morphology
The particles surface morphology is determined by utilizing scanning 
electron microscopy (SEM) where 200 kV is set for placing the 
nanoformulation samples in an air-dried condition on a copper grid.
Drug content
The total amount of drug present in nanoformulation is estimated 
by spectrophotometrically. An aliquot range from 0.50 ml of 
nanoformulation is evaporated under reduced pressure at 35°C. The 
resultant residue is then dissolved in water, which is filtered through a 
0.45 µm size filter and assayed spectrophotometrically at 263 nm.
Drug entrapment efficiency
It is also known as association efficiency. The drug-loaded 
nanosuspension is centrifuged at 3500–4000 rpm for 30 min, where the 
supernatant is collected. Is assayed for non-bound drug concentration 
by UV spectrophotometer.
In vitro release studies
In vitro diffusion studies (release studies) are determined using diffusion 
apparatus. A semipermeable membrane was supported on a ring of 
diffusion cell and the sample was kept on a membrane in such a way 
backing layer was phased toward donor compartment. The glass beaker 
was filled with 100 ml of phosphate buffer of pH: 6.8 at a temperature 
37°C sample of 2 ml was withdrawn at regular intervals from glass 
beaker for analysis. 2 ml of phosphate buffer was replaced immediately 
after sampling to maintain volume equal to 100 ml. The absorbance of 
sampling was measured at 263 nm using UV spectrophotometer.
In vivo animal studies
Animals weighing 150–200 g of male rats of Wistar strain are selected for 
the study where housed in a controlled room temperature with 12:12-h 
light/dark cycles is maintained, supplement of food and water is done. The 
care for in laboratory is given according to the Animal Ethical Committee 
which is formed for Control and Supervision of Experiments on Animals, 
Chennai, and Govt. of India. The protocol for the experimental is approved 
by the Institutional Ethical Committee. Rotenone to induce parkinsonism 
is purchased from Sigma-Aldrich Chemical Company (Bangalore, India).
Dosing and treatment





and administered intraperitoneally for 10 days.
•	 Group	C:	Animals	received	nanosuspension	(PHC3)	(drug	equivalent	
to 0.8 mg/ml/day/kg) are given orally by gavage once daily 30 min 
before rotenone (2.5 mg/kg) dissolved in saline for 10 days.
Table 2: Particle size nanoformulation
S. No Formulation Ratio Particle size
1 PHC1 1:1 646
2 PHC2 1:2 523
3 PHC3 1:3 188
4 PHC4 1:4 326
5 PHC5 1:5 452
Table 3: Zeta potential nanoformulation
S. No Formulation Ratio Zeta potential
1 PHC1 1:1 62.6
2 PHC2 1:2 52.8
3 PHC3 1:3 46.7
4 PHC4 1:4 45.4
5 PHC5 1:5 44.7
Table 4: Drug content and entrapment efficiency of nanoparticle









Table 5: In vitro release study of nanofrmulations
S. No Time (h) % cumulative drug release
PHC1 PHC2 PHC3 PHC4 PHC5
1 0 0 0 0 0 0
2 1 9.8±1.2 8.1±1.3 7.2±1.7 6.7±1.5 6.1±1.3
3 2 26.1±1.8 11.2±1.2 10.8±1.5 11.1±2.3 9.2±1.6
4 4 48.2±1.4 33.7±1.5 21.2±1.3 22.7±2.6 15.9±2.1
5 6 54±1.7 46.1±1.4 33.5±0.9 30±0.9 25.7±1.9
6 8 77.4±1.2 57.5±1.3 42.1±2.2 43.1±1.2 36.4±1.8
7 12 98.6±1.6 73.1±1.5 54.6±1.9 57.3±1.6 48.3±2.1
8 16 - 84.3±1.2 62.3±2.2 63.8±1.1 60.5±1.4
9 20 - 97.4±1.7 75.7±1.3 72.2±1.4 68.7±1.3
10 24 - - 85.2±1.5 80.2±1.3 75.1±1.7
*±values indicate the triplicate trials
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•	 Group	D:	Animals	received	pramipexole	dihydrochloride	pure	drug	
(1 mg/kg body weight/day) and hesperidin pure drug (1 mg/kg) 
were administered by oral gavage once daily 30 min before rotenone 




DSC studies were carried out for pramipexole dihydrochloride, 
hesperidin, chitosan, and mixtures of pramipexole dihydrochloride-
chitosan-hesperidin by DSC. It was found that there was no interaction 
between drug and polymer (Figs. 1-4).
FTIR
FTIR spectroscopic studies were carried out for the standard 
pramipexole dihydrochloride, chitosan, TPP, and a mixture of 
pramipexole dihydrochloride-chitosan-TPP by KBr pellet technique 
using FTIR spectrophotometer. FTIR spectrum of standard 
is compared with that of mixture and found that there is no 
interference (Figs. 5-8).
Fig. 2: Differential scanning calorimetric spectrum of pramipexole dihydrochloride
Fig. 3: Differential scanning calorimetric spectrum of hesperidin
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Preparation of pramipexole dihydrochloride and hesperidin 
nanoformulation
Pramipexole dihydrochloride and hesperidin-loaded chitosan 
nanoparticles were prepared by ionotropic gelation method. Two 
batches of process optimized formulations were prepared with 
varying concentrations of chitosan. The prepared nanoparticle 
formulations were found to be turbid and stable. Moreover, they were 
packed in air-tight containers and stored in a cool place and used for 
further studies.
Characterization of nanoparticles
Measurement of the particle size of nanoparticles
The particle sizes of prepared nanoparticles were measured from the 
microphotograph of 100 particles. The particle size ranged from 252 nm 
Fig. 4: Differential scanning calorimetric spectrum of mixture with drug and polymer
Fig. 5: Fourier transform infrared of pramipexole dihydrochloride
Fig. 6: Fourier transform infrared of chitosan
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to 432 nm for various batches. The increase in the concentration of the 
polymer ratio caused an increase in particle size (Table 2).
Zeta potential
The zeta potential of PHC3 is 46.7 having better particle, so this 
formulation may be the best formulation (Table 3).
Drug content and entrapment efficiency
The total drug content of PHC3 is having 0.364 with entrapment 
efficiency of 72.8 shows a better drug content with better entrapment 
efficiency (Table 4).
SEM
SEM analysis of the prepared formulation was carried out to understand 
the morphology of nanoparticles. In the SEM images indicate that the 
nanoparticles were discrete, uniform, and spherical with a smooth 
surface. Hence, the images show that proper expected shape has been 
achieved (Figs. 9 and 10).
In vitro release studies
In vitro diffusion studies (drug release studies) were performed using 
diffusion apparatus. A semipermeable membrane was supported on a 
ring of diffusion cell and the sample was kept on a membrane in such 
a way backing layer was phased toward donor compartment. The 
glass beaker was filled with 100 ml of phosphate buffer of pH=6.8 at 
Fig. 7: Fourier transform infrared of hesperidin
Fig. 8: Fourier transform infrared of pramipexole dihydrochloride, hesperidin, and chitosan
Fig. 9: Scanning electron microscopy images of pramipexole 
dihydrochloride and hesperidin in chitosan nanoparticles
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a temperature 37°C sample of 2 ml was withdrawn at regular intervals 
from glass beaker for analysis. 2 ml of phosphate buffer was replaced 
immediately after sampling to maintain volume equal to 100 ml. 
The absorbance of sampling was measured at 263 nm using UV 
spectrophotometer (Table 5).
In this, PHC1 shows the highest drug release followed by PHC2 due to 
low polymer concentration. PHC4 and PHC5 show less drug release due 
to higher polymer concentration. The in vitro release of PHC3 is 85.2% 
showed an initial burst release of approximately 60% in the first 8 h, 
followed by a slow and much reduced additional release for about 24 
h (Fig. 11).
In vivo studies
Histopathological evaluation of rat brain in experimental animal
Histopathology images of rat brain in experimental animal are in 
Fig. 12, it was observed that the rotenone-induced Group B rat 
shows degeneration of nucleus along with cell shrinkage due to the 
accumulation of more nucleus in one cell. This nanosuspension-treated 
Group C has been reversed when compared to induced Group B, whereas 
Group D shows same as control, which supports the nanoformulation 
treatment reveals the rotenone-induced degeneration of neural cells 
which further supports the nanosuspension is more effective in the 
treatment of parkinsonism diseases.
CONCLUSION
There was no incompatibility observed between drug and polymer. 
The particle size was found to be 188 nm for formulation PHC3. The 
entrapment efficiency was found to be 72.8% for formulation PHC3. 
More than 85% of drug release was observed in PHC3. Therefore, PHC3 
was chosen as the best formulation as they have better release than 
other formulations. The result supports the biodegradable polymers 
which help in the production of more controlled release dosage form 
for the treatment in Parkinson’s disease.
REFERENCES
1. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of 
peptides through the blood-brain barrier with colloidal polymer 
particles (nanoparticles). Brain Res 1995;674:171-4.
2. Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, 
et al. Characterization of endocytosis of transferrin-coated PLGA 
nanoparticles by the blood-brain barrier. Int J Pharm 2009;379:285-92.
3. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and 
PBCA nanoparticles: Preparation, optimization, characterization, 
in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 
2010;76:189-99.
4. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. Targeted 
nanoparticles for drug delivery through the blood-brain barrier for 
Alzheimer’s disease. J Control Release 2005;108:193-214.
5. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central 
nervous system: A review. J Pharm Pharm Sci 2003;6:252-73.
6. Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, et al. 
Development and evaluation of rivastigmine loaded chitosan 
nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6-15.
7. Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T, 
et al. Characterization and evaluation of chitosan nanoparticles for 
dopamine brain delivery. Int J Pharm 2011;419:296-307.
8. Anantharam V, Lehrmann E, Kanthasamy A, Yang Y, Banerjee P, 
Becker KG, et al. Microarray analysis of oxidative stress regulated genes 
in mesencephalic dopaminergic neuronal cells: Relevance to oxidative 
damage in Parkinson’s disease. Neurochem Int 2007;50:834-47.
9. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms 
of antioxidants: Experimental approaches and model systems. J Cell 
Mol Med 2010;14:840-60.
10. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. 
Cell 2005;120:483-95.
11. Hamid AA, Aiyelaagbe OO, Usman LA, Ameen OM, Lawal A. 
Antioxidants: Its medicinal and pharmacological applications. Afr J 
Pure Appl Chem 2010;4:142-51.
12. Kuppusamy T, Jagadhesan N, Udaiyappan J, Thamilarasan M, 
Fig. 10: Scanning electron microscopy images of pramipexole 
dihydrochloride and hesperidin in chitosan nanoparticles
Fig. 11: In vitro drug release studies
Fig. 12: Plates containing histopathological studies in 
experimental animals. (a) Control (×400) (normal saline), 
(b) Rotenone (2.5 mg/kg), (c) PHC3 (drug equivalent 
to 0.8 mg/ml)+rotenone (2.5mg/kg), (d) Pramipexole 






Asian J Pharm Clin Res, Vol 11, Special Issue 4, 2018, 133-140
 Somasundaram and Kavi 
Mohammed EM. Antioxidant and anti-inflammatory potential of 
hesperidin against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-
induced experimental Parkinson’s disease in mice. Int J Nutr Pharmacol 
Neurol Dis 2013;3:294.
13. Essa MM, Vijayan RK, Castellano-Gonzalez G, Memon MA, Braidy N, 
Guillemin GJ, et al. Neuroprotective effect of natural products against 
Alzheimer’s disease. Neurochem Res 2012;37:1829-42.
14. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical 
evidence for 6-hydroxydopamine to be an endogenous toxic 
factor in the pathogenesis of Parkinson’s disease. J Neural Transm 
Suppl 1995;46:297-314.
15. Gao X, Qian J, Zheng S, Changyi Y, Zhang J, Ju S, et al. Overcoming 
the blood-brain barrier for delivering drugs into the brain by using 
adenosine receptor nanoagonist. ACS Nano 2014;8:3678-89.
16. Orrego C, Salgado N, Valencia J, Giraldo G, Giraldo O. Novel chitosan 
membranes as support for lipases immobilization: Characterization 
aspects. Carbohydr Polym 2010;79:9-16.
17. Sarvaiya J, Agrawal YK. Chitosan as a suitable nanocarrier material for 
anti-alzheimer drug delivery. Int J Biol Macromol 2015;72:454-65.
18. Sailaja AK, Amareshwar P, Chakravarty P. Different techniques used 
for the preparation of nanoparticles using natural polymers and their 
application. Int J Pharm Pharm Sci 2011;3:45-50.
19. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly 
(ethylene)-glycol conjugated nanoparticles of noscapine improve 
biological half-life, brain delivery and efficacy in glioblastoma cells. 
Nanomedicine 2012;12:600-4.
20. Shakeel F, Ramadan W, Shafiq S. Solubility and dissolution 
improvement of aceclofenac using different nano carriers. J Bioequiv 
Availab 2009;1:39-43.
21. Rajan M, Raj V. Encapsulation, characterization and in-vitro release 
of anti-tuberculosis drug using chitosan-poly ethylene glycol 
nanoparticles. Int J Pharm Pharm Sci 2012;4:255-9.
22. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation 
method intended for the entrapment of hydrophilic drugs into 
nanoparticles. Eur J Pharm Sci 2005;24:67-75.
23. Yadav KS, Sawant KK. Modified nanoprecipitation method for 
preparation of cytarabine-loaded PLGA nanoparticles. AAPS 
PharmSciTech 2010;11:1456-65.
24. Rajan M, Raj V. Encapsulation, characterisation and in-vitro release 
of anti-tuberculosis drug using chitosan-poly ethylene glycol 
nanoparticles. Int J Pharm Pharm Sci 2012;4:255-9.
